Michael Biermer

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Venues

Journal of clinical pharmacology

Gut

This page only lists publications with an associated author ORCID identifier.

Publications

Loey Lung-Yi Mak, Christine I Wooddell, Oliver Lenz, Thomas Schluep, James Hamilton, Heather L Davis, Xianhua Mao, Wai Kay Seto, Michael Biermer, Man Fung Yuen
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut (2024)
Harry L A Janssen, Jin-Lin Hou, Asselah Tarik, Henry L Y Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald G Nahass, Stefan Bourgeois, Maria Buti, Pietro Lampertico, Oliver Lenz, Thierry Verbinnen, Joris Vandenbossche, Willem Talloen, Ronald Kalmeijer, Maria Beumont, Michael Biermer, Umesh Shukla
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut (2023)
Thomas N Kakuda, Atef Halabi, Gernot Klein, Madhu Sanga, Carine Guinard-Azadian, Monika Kowalik, Katja Nedoschinsky, Julius Nangosyah, Emmanuel Njumbe Ediage, Vera Hillewaert, Peter Verboven, Ivo Goris, Jan Snoeys, Martyn Palmer, Michael Biermer
Pharmacokinetics of Jnj-73763989 And Jnj-56136379 (Bersacapavir) In Participants With Moderate Hepatic Impairment. Journal of clinical pharmacology (2023)
Thomas N Kakuda, Atef Halabi, Gernot Klein, Madhu Sanga, Carine Guinard-Azadian, Monika Kowalik, Katja Nedoschinsky, Julius Nangosyah, Emmanuel Njumbe Ediage, Vera Hillewaert, Peter Verboven, Ivo Goris, Jan Snoeys, Martyn Palmer, Michael Biermer
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment. Journal of clinical pharmacology (2023)

Michael Biermer.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Michael Biermer